×
Hero Background

Pituitary Cancer Companies

ID: MRFR/Pharma/1126-HCR
90 Pages
Rahul Gotadki
October 2025

Pituitary Cancer companies are at the forefront of advancing research, treatment, and support for individuals facing pituitary cancer. Committed to improving patient outcomes, these organizations focus on innovative therapies, diagnostics, and awareness initiatives to enhance the quality of care for those affected by pituitary cancer.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Pituitary Cancer Market

Pituitary cancer Key Companies

 

Latest Pituitary cancer Companies Update


Varian Medical Systems' Halcyon™ radiotherapy system receives FDA approval for pituitary tumors: December 2023 approval expands treatment options for pituitary cancer patients, offering a precise and advanced radiation therapy solution.


Siemens Healthineers announces collaboration with Radiomics AI startup QBio for pituitary tumor analysis: January 2024 partnership aims to leverage AI to improve diagnosis and treatment planning for pituitary cancers.


ACoS Biopharma launches Phase 2 clinical trial for AC101 in acromegaly, a hormone disorder often associated with pituitary tumors: February 2023 development marks a step forward in exploring new drug therapies for pituitary cancer-related conditions


List of Pituitary Cancer Key Companies in the Market



  • Amgen Inc. (US)

  • Astellas Pharma Inc. (Japan)

  • Eli Lilly and Company (US)

  • Bristol-Myers Squibb Company (US)

  • Celgene Corporation (US)

  • Merck & Co., Inc. (US)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US), AstraZeneca (UK)

  • Mylan N.V. (US)

  • Johnson & Johnson Services, Inc. (US)

  • Onxeo (France)

  • Ipsen Pharmaceuticals (France)

  • Salix Pharmaceuticals, Inc. (US)

  • Strides Pharma Science Limited (India)